Aktienanalyse zu Immunome Inc (IMNM)IMNMImmunome Inc

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immunome Inc is currently a hold. The stock is trading at $16.47, down 15.75% over the last five days, with a very low RSI of 13.703 indicating it is oversold. However, the company has a strong cash position of $582.7 million, which can fund operations into 2028, and positive catalysts from FDA acceptance of its drug application. The main risk is the negative net income, which was -$73.1 million in Q2 2026, indicating ongoing financial challenges.